烟波克昔/诺香草胺(Nicoboxil/Nonivamide) - 在研适应症：关节炎，滑囊炎，腰痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nicoboxil、beta-Butoxyethyl nicotinate、Finalgon

靶点-

作用机制-

治疗领域

神经系统疾病心血管疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

关节炎滑囊炎腰痛+ [3]

非在研适应症-

原研机构

Sanofi

在研机构

Sanofi

非在研机构-

最高研发阶段批准上市

首次获批日期

德国 (2012-07-11),

关节炎滑囊炎腰痛+ [3]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C29H44N2O6

InChIKeyGBZLDDMGSWUIKV-UHFFFAOYSA-N

CAS号93746-32-8

关联

2

项与烟波克昔/诺香草胺相关的临床试验

NCT02300311

/ Completed临床3期

A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain

To evaluate efficacy of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide) versus placebo in patients with acute low back pain. To investigate the safety and tolerability of repeated use of Finalgon® cream (1.08% Nicoboxil/ 0.17% Nonivamide).

开始日期2015-01-01

申办/合作机构

Boehringer Ingelheim GmbH

NCT01708915

/ Completed临床3期

A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2.5% Nicoboxil/0.4% Nonivamide Versus 2.5% Nicoboxil, 0.4% Nonivamide and Placebo in Patients 18 to 65 Years of Age With Acute Low Back Pain

The aim of this study is to assess the efficacy and tolerability of Nicoboxil/Nonivamide ointment in comparison to Nicoboxil, Nonivamide, and placebo ointments for the treatment of acute low back pain.

开始日期2012-10-01

申办/合作机构

Boehringer Ingelheim GmbH

100 项与烟波克昔/诺香草胺相关的临床结果

登录后查看更多信息

100 项与烟波克昔/诺香草胺相关的转化医学

登录后查看更多信息

100 项与烟波克昔/诺香草胺相关的专利（医药）

登录后查看更多信息

17

项与烟波克昔/诺香草胺相关的文献（医药）

2021-11-01·International Journal of Sports Medicine4区 · 医学

No Influence of Nonivamide-nicoboxil on the Peak Power Output in Competitive Sportsmen

4区 · 医学

Article

作者: Schörkmaier, Theresa ; Bloch, Wilhelm ; Wahl, Yvonne ; Brinkmann, Christian ; Wahl, Patrick

AbstractRecent studies have shown that the oxygenated hemoglobin level can be enhanced during rest through the application of nonivamide-nicoboxil cream. However, the effect of nonivamide-nicoboxil cream on oxygenation and endurance performance under hypoxic conditions is unknown. Therefore, the purpose of this study was to investigate the effects of nonivamide-nicoboxil cream on local muscle oxygenation and endurance performance under normoxic and hypoxic conditions. In a cross-over design, 13 athletes (experienced cyclists or triathletes [age: 25.2±3.5 years; VO2max 62.1±7.3 mL·min−1·kg−1]) performed four incremental exercise tests on the cycle ergometer under normoxic or hypoxic conditions, either with nonivamide-nicoboxil or placebo cream. Muscle oxygenation was recorded with near-infrared spectroscopy. Capillary blood samples were taken after each step, and spirometric data were recorded continuously. The application of nonivamide-nicoboxil cream increased muscle oxygenation at rest and during different submaximal workloads as well as during physical exhaustion, irrespective of normoxic or hypoxic conditions. Overall, there were no significant effects of nonivamide-nicoboxil on peak power output, maximal oxygen uptake or lactate concentrations. Muscle oxygenation is significantly higher with the application of nonivamide-nicoboxil cream. However, its application does not increase endurance performance.

2016-05-01·European Journal of Applied Physiology

Topical application of cream containing nonivamide and nicoboxil does not enhance the performance of experienced cyclists during a 4-km time-trial

Article

作者: Holmberg, Hans-Christer ; Zinner, Christoph ; Sperlich, Billy

PURPOSETopical application of nonivamide-nicoboxil cream to resting legs has been shown to enhance the level of oxygenated haemoglobin in leg muscles 15 min later. Here, we examined whether such application improves the performance of experienced cyclists in a subsequent 4-km time-trial.METHODSNine male cyclists [26 ± 8 years; 176 ± 9 cm; 73.5 ± 12.8 kg; peak oxygen uptake: 50.7 ± 4.0 mL min(-1) kg(-1) (mean ± SD)] performed three 4-km time-trials on an ergometer with either topical application of nonivamide-nicoboxil cream (CREAM) or cream without active components (SHAM) to both their thigh muscles or no application (CONTROL).RESULTSOnly the skin temperature immediately before and after the time-trial was higher with cream than SHAM and CONTROL (best p < 0.001, best d = 1.16). All other parameters evaluated, i.e., the average power output during the time-trial (p > 0.05, best d = 0.08), the tissue saturation index of the m. vastus lateralis (p > 0.05, best d = 0.57), cardiac output, heart rate, oxygen uptake, blood lactate concentration, and perceived exertion (p > 0.05, best d = 1.1) were similar under all three conditions.CONCLUSIONSOur present findings reveal that topical application of cream containing nonivamide and nicoboxil to the thighs of cyclists prior to a 4-km time-trial does not improve their power output, saturation of the m. vastus lateralis with oxygen, oxygen uptake, heart rate, cardiac parameters, or perceived level of exertion.

2010-12-01·Phytotherapy Research2区 · 医学

Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain

2区 · 医学

Article

作者: Beate Beime ; Thomas Weiser ; Sigrun Chrubasik

AbstractTopical capsaicin is an established treatment option for various pain conditions. In a randomized double‐blind multi‐centre study, 281 patients suffering from chronic soft tissue pain were treated either with a cream containing capsaicin 0.05% (‘Finalgon® CPD Wärmecreme’, n = 140) or placebo (n = 141). Of these, 151 were excluded from the ITT analysis, as they had in addition to their soft‐tissue pain, pain of other origin. The primary outcome measure was a positive treatment response, defined as a pain sum score reduction of 30% or more. After 3 weeks of treatment, the median pain sum score had decreased by 49% (capsicum group) and 23% (placebo group) (ITT analysis, p = 0.0006). The odds ratio of the responders in favour for capsaicin was 4.3 (CI 97.5% lower limit 1.9, p < 0.0001). Improvements in the secondary efficacy measures confirmed the results. Likewise, all outcome measures had significantly more improved in the capsaicin‐treated compared with the placebo‐treated chronic back pain sufferers. All patients were included in the safety assessments. More adverse events occurred in the capsicum group (n = 13) than in the placebo group (n = 6). The capsaicin cream was generally well tolerated. The results indicate that capsaicin cream is useful in patients with chronic soft tissue pain and is also efficacious in patients with chronic back pain for which effectiveness was already demonstrated in earlier clinical trials.

100 项与烟波克昔/诺香草胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	M02AB	DB12911

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
关节炎	德国	Sanofi	2012-07-11
滑囊炎	德国	Sanofi	2012-07-11
腰痛	德国	Sanofi	2012-07-11
坐骨神经痛	德国	Sanofi	2012-07-11
腱鞘炎	德国	Sanofi	2012-07-11
血管疾病	德国	Sanofi	2012-07-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02300311 (TOPICAL NONIVAMIDE/NICOBOXIL, CTgov)	临床3期	急性腰痛	138	placebo matching nonivamide + nicoboxil (Finalgon cream)	遞鑰廠構襯範簾簾廠糧(艱壓窪鏇構艱鹹觸醖淵) = 築鹽鬱蓋鑰醖淵製範醖窪襯餘鬱鹹鏇構廠壓獵 (網廠淵淵鏇鏇蓋餘鑰構, 鹹膚窪餘網蓋衊鑰簾醖 ~ 襯積積觸蓋顧網鏇蓋鬱) 更多	-	2016-09-13
NCT01708915 (CTgov)	临床3期	急性腰痛	805	placebo matching nonivamide + nicoboxil (Placebo)	餘繭製窪鬱繭鬱憲鹽鬱(獵廠餘鬱憲鬱窪簾衊築) = 構鹽蓋餘獵廠艱艱糧鹽鹽繭構範鏇齋餘構鬱獵 (餘構獵醖範窪遞衊網鹽, 繭鹹積鹽鏇簾齋製製壓 ~ 憲鏇獵膚觸醖鹽網簾鏇) 更多	-	2014-05-15
NCT01708915 (CTgov)	临床3期	急性腰痛	805	nicoboxil (Nicoboxil)	餘繭製窪鬱繭鬱憲鹽鬱(獵廠餘鬱憲鬱窪簾衊築) = 鹽觸選願簾憲鏇築製醖鹽繭構範鏇齋餘構鬱獵 (餘構獵醖範窪遞衊網鹽, 鏇範醖願網範範獵遞齋 ~ 齋鑰鹽蓋憲夢獵廠餘衊) 更多	-	2014-05-15